Market Newsdesk

Video segment examines current Ebola outbreak concerns, unmet need surrounding the Bundibugyo strain and Ampligen’s previously published antiviral research

Discussion highlights Ampligen’s immune-modulating mechanism, prior Biosafety Level 4 findings and potential applicability across emerging viral threats

New Ebola-focused corporate presentation highlighting Ampligen’s antiviral research and preparedness potential is now accessible

here

Access the ‘What This Means’ video segment

here

OCALA, Fla., June 04, 2026 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the release of a Virtual Investor “What This Means” video segment featuring AIM Chief Executive Officer Thomas Equels, Consulting Medical Officer Charles Lapp, MD, and Consulting Science Officer Christopher Nicodemus, MD.

As part of the video segment, management discusses the ongoing Bundibugyo (“BDBV”) Ebola outbreak and the growing concern surrounding the lack of approved targeted therapies or vaccines specifically addressing this strain. The discussion explores the broader public health implications of emerging viral outbreaks, including containment challenges, cross-border transmission risks and the importance of preparedness initiatives designed to support healthcare systems and vulnerable populations.

Equels stated: “BDBV is a lethal, out-of-control disease. Infected patients can receive aggressive supportive care, but there are no approved vaccines, therapies or meaningful drugs designed to help mitigate the spread of the outbreak. A prophylactic or early-onset therapeutic is clearly needed. We believe that Ampligen has the potential to be that therapeutic, based on studies such as one conducted at the US government USAMRIID facility, which showed that intraperitoneal Ampligen could have a prophylactic and/or early-onset impact on Ebola disease. Further, intranasal Ampligen might more easily provide preventive protection, especially in regions of the world where infusion therapy is impractical. ”

This video segment reviews previously published Biosafety Level 4 preclinical findings demonstrating 100% protective survival with early administration of Ampligen in a lethal Ebola mouse model. Management discusses Ampligen’s mechanism as a PAMP restricted TLR3 agonist designed to activate innate immune pathways and shares perspective on why the Company believes the approach may potentially have relevance across multiple Ebola variants and other emerging viral threats.

The discussion highlights AIM’s previously established regulatory and scientific groundwork supporting the program, including orphan drug designation from both the U.S. Food and Drug Administration and European Medicines Agency for Ebola virus disease. The video segment further explores the potential future role of scalable antiviral and immune-modulating approaches in broader biodefense, preparedness and emerging infectious disease response initiatives.

AIM has made available an updated Ebola-focused corporate presentation further highlighting Ampligen’s previously published antiviral research, immune-modulating mechanism and broader preparedness potential in emerging viral threats, as well as intravenous and intranasal Ampligen human safety studies. The Ebola-focused presentation is available under the Presentations section on the Investors page of the Company’s website (aimimmuno.com).

The Virtual Investor “What This Means” video segment featuring AIM ImmunoTech is now available here.

About AIM ImmunoTech Inc.

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of its lead product, Ampligen^® (rintatolimod), for the treatment of late-stage pancreatic cancer, a lethal and unmet global health problem. Ampligen is a dsRNA and highly selective TLR3 agonist immuno-modulator that has shown broad-spectrum activity in clinical trials.

For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that involve a number of risks and uncertainties. The video segment may also contain forward-looking statements. Any forward-looking statements set forth in this press release speak only as of the date hereof and any forward-looking statements in the video segment speak only as of the date thereof. Such forward-looking statements may include statements relating to: Ampligen’s potential efficacy and applicability in the treatment of Ebola virus disease; the potential for prophylactic or early-onset therapeutic applications; the timing of commencement, enrollment, completion, and results of clinical trials; intellectual property expansion and regulatory progress; and timing for receiving government approvals, if at all. For all forward-looking statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. All statements in this press release and the video segment other than statements of historical fact, including statements regarding the potential of Ampligen’s mechanism of action, anticipated regulatory milestones, our future results of operations and financial position, our business strategy and plans, and our objectives for future operations, are forward-looking statements. For both this press release and the video segment, words such as “believe,” “may,” “might,” “will,” “could,” “should,” “can,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “envision,” “potential” and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof, except as required by applicable law. The Company is in various stages of seeking to determine whether Ampligen will be effective in the treatment of multiple types of viral diseases, cancers, and immune-deficiency disorders, and disclosures in the Company’s reports filed with the SEC, on its website, and in its press releases set forth its current and anticipated future activities. These activities are subject to change for a number of reasons. Significant additional testing and trials will be required to determine whether Ampligen® will be effective in the treatment of these conditions, including Ebola virus disease. Results obtained in preclinical studies do not necessarily predict results in humans. Human clinical trials will be necessary to prove whether or not Ampligen® will be efficacious in humans. No assurance can be given as to whether current or planned clinical trials will be successful or yield favorable data, and the trials are subject to many factors including lack of regulatory approval(s), lack of study drug, lack of adequate funding, or a change in priorities at the institutions sponsoring other trials. Even if these clinical trials are initiated, the Company cannot assure that the clinical studies will be successful or yield any useful data. No assurance can be given that the findings in preliminary studies will prove true or that such studies will yield favorable results, or that future studies will not result in findings that are different from those reported in the studies referenced in the Company’s reports filed with the SEC, on the Company’s website, and in its press releases. Operating in foreign countries carries with it a number of risks, including potential difficulties in enforcing intellectual property rights. The Company cannot assure that its potential foreign operations will not be adversely affected by these risks.

For a detailed discussion of these and other risk factors, please review the “Risk Factors” section in the Company’s most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q filed with the SEC. These filings are available at www.sec.gov and www.aimimmuno.com. You should not place undue reliance on any forward-looking statements. The information found on the Company’s website or on other websites referenced or linked to in this press release (including in the video segment) is not incorporated by reference into this press release and such information is referenced or linked for reference purposes only.

SAN DIEGO, June 04, 2026 (GLOBE NEWSWIRE) — LPL Financial LLC announced today that financial advisors Scott Gilliam, CFP^® and Travis Blessing, AIF^®, have launched a new independent practice, Align Private Wealth, through affiliation with LPL Financial’s broker-dealer and Registered Investment Advisor (RIA) platform. The team reported serving approximately $2 billion in advisory plan assets* and joins LPL from PNC Private Bank.

Based in Greenwood, Ind., just outside of Indianapolis, Gilliam and Blessing bring a combined 40 years of industry experience to the new endeavor. Align Private Wealth serves high-net-worth and ultra-high-net-worth families, as well as individuals, business owners and multigenerational households seeking personalized financial guidance.

“Our goal is to build deep, long-term relationships where we truly understand every aspect of our clients’ lives — not just their finances,” said Gilliam. “We’ve intentionally designed our practice to work with a limited number of families so we can be fully embedded in their decision-making, helping them navigate everything from wealth planning to generational transitions.”

The team takes a goals-based, planning first approach, working closely with each client through ongoing conversations and proactive check-ins to ensure strategies remain aligned with evolving needs.

Why They Made the Move to LPL

After a period of extensive due diligence, the Align Private Wealth team chose LPL Financial for its ability to support full independence while providing the scale and resources needed to enhance the client experience.

“Independence is incredibly important to us — we wanted the ability to build our business entirely around our clients,” said Blessing. “LPL’s platform gives us the flexibility, technology and support to do exactly that, while enhancing how we deliver customized planning and tax-aware strategies.”

Gilliam added, “We evaluated multiple firms, but LPL stood out for its reputation and its focus on helping advisors grow businesses that are built for clients, not for a firm. That client-first mentality was critical for us as we launched Align Private Wealth.”

In addition to having access to LPL’s integrated wealth management platform, the team values the ability to incorporate advanced planning tools and technology to further customize strategies and deliver more holistic advice.

Marc Cohen, chief growth officer at LPL, said, “We welcome Scott, Travis and the Align Private Wealth team to the LPL community. Their commitment to building deep, personalized relationships and delivering comprehensive, goals-based guidance reflects the kind of client-first approach we are proud to support. We look forward to helping them grow their business through our bespoke high-net-worth capabilities and continue delivering meaningful outcomes for the families they serve.”

Outside of the office, Gilliam enjoys coaching competitive travel baseball and spending time boating on Lake Cumberland with his wife, Sondra, and their two sons. Blessing and his wife, Cheryl, recently became empty nesters and enjoy traveling together and relaxing by the ocean.

Related

Advisors, learn how LPL Financial can help take your business to the next level.

About LPL Financial

LPL Financial Holdings Inc. (Nasdaq: LPLA) is among the fastest growing wealth management firms in the U.S. As a leader in the financial advisor-mediated marketplace, LPL supports more than 32,000 financial advisors and the wealth management practices of approximately 1,100 financial institutions, servicing and custodying approximately $2.3 trillion in brokerage and advisory assets on behalf of approximately 8 million Americans. The firm provides a wide range of advisor affiliation models, investment solutions, fintech tools and practice management services, ensuring that advisors and institutions have the flexibility to choose the business model, services, and technology resources they need to run thriving businesses. For further information about LPL, please visit www.lpl.com/.

Securities and advisory services offered through LPL Financial LLC (“LPL Financial”), a registered investment adviser and broker-dealer. Member FINRA/SIPC. Align Private Wealth and LPL Financial are separate entities.

Throughout this communication, the terms “financial advisors” and “advisors” are used to refer to registered representatives and/or investment advisor representatives affiliated with LPL Financial.

We routinely disclose information that may be important to shareholders in the “Investor Relations” or “Press Releases” section of our website.

*Value approximated based on asset and holding details provided to LPL from end of year, 2025.

Media Contact:
 
[email protected] 

Tracking # 1116296

The Mudra Pro is now available for pre-order to qualified customers and OEM customers

Yokneam Illit, Israel, June 04, 2026 (GLOBE NEWSWIRE) — Wearable Devices Ltd. (Nasdaq: WLDS, WLDSW) (“Wearable Devices” or the “Company”), a technology growth company specializing in artificial intelligence (“AI”)-powered touchless sensing wearables, today announced the launch of the Mudra Pro for early pre-orders.

The Mudra Pro provides original equipment manufacturers (“OEMs”), enterprise innovation teams, researchers, and developers with a dedicated destination to review product specifications, software development kit capabilities, and pilot-oriented resources. Submitting details enables qualified customers and OEMs to begin pilot discussions with the Company’s Sales and Business Development teams and seek early access to Mudra Pro.

Mudra Pro introduces a thinner, ergonomic band design. In addition to its electromyography  and inertial measurement unit sensors, Mudra Pro adds a new photoplethysmography (“PPG”) sensor. PPG is an established optical sensing method that measures blood-volume changes beneath the skin using light. It is commonly used to monitor heart rate, heart rate variability, blood oxygen trends, and other cardiovascular signals. When combined with motion and muscle-activity sensing, PPG may also support gesture and intent detection.

“We are delighted to continue expanding our product portfolio with Mudra Pro,” said Guy Wagner, President and Chief Scientific Officer of Wearable Devices. “Together with Mudra Studio, it gives customers and developers the development tools needed to reduce technical barriers, rapidly validate use cases, and accelerate the path from concept to commercialization.”

Mudra Pro is an outcome of the Company’s ai6 Labs initiative, focused on advancing AI-native technologies through neural sensing, wearable computing, and intent-based interfaces.

To learn more, review Mudra Pro technical specifications, and submit pre-order details for early access, please visit: https://mudra-band.com/pages/mudra-band-pro

About Wearable Devices

Wearable Devices Ltd. (Nasdaq: WLDS, WLDSW) is a growth company pioneering human-computer interaction through its AI-powered neural input touchless technology. Leveraging proprietary sensors, software, and advanced AI algorithms, the Company’s consumer products – the Mudra Band and Mudra Link – are defining the neural input category both for wrist-worn devices and for brain-computer interfaces. These products enable touch-free, intuitive control of digital devices using gestures across multiple operating systems.

Operating through a dual-channel model of direct-to-consumer sales and enterprise licensing and collaborations, Wearable Devices empowers consumers with stylish, functional wearables for enhanced experiences in gaming, productivity, and extended reality (“XR”). In the business sector, the Company provides enterprise partners with advanced input solutions for immersive and interactive environments, from augmented reality/virtual reality/XR to smart environments. By setting the standard for neural input in the XR ecosystem, Wearable Devices is shaping the future of seamless, natural user experiences across some of the world’s fastest-growing tech markets. The newly launched ai6 Labs ecosystem accelerates this vision by integrating research, products, and AI breakthroughs. Wearable Devices’ ordinary shares and warrants trade on the Nasdaq Capital Market under the symbols “WLDS” and “WLDSW,” respectively.

Forward-Looking Statements Disclaimer

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the “safe harbor” created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “should,” “could,” “seek,” “intend,” “plan,” “goal,” “estimate,” “anticipate” or other comparable terms. For example, we are using forward-looking statements when we discuss the potential benefits, advantages and capabilities of Mudra Pro, and that it gives our business customers the development tools needed to reduce technical barriers, rapidly validate use cases, and accelerate the path from concept to commercialization. All statements other than statements of historical facts included in this press release regarding our strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: the trading of our ordinary shares or warrants and the development of a liquid trading market; our ability to successfully market our products and services; the acceptance of our products and services by customers; our continued ability to pay operating costs and ability to meet demand for our products and services; the amount and nature of competition from other security and telecom products and services; the effects of changes in the cybersecurity and telecom markets; our ability to successfully develop new products and services; our success establishing and maintaining collaborative, strategic alliance agreements, licensing and supplier arrangements; our ability to comply with applicable regulations; and the other risks and uncertainties described in our annual report on Form 20-F for the year ended December 31, 2025, filed on March 12, 2026 and our other filings with the Securities and Exchange Commission. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Investor Relations Contact:

Michal Efraty

[email protected]

DUMAS, Texas, June 04, 2026 (GLOBE NEWSWIRE) — Duos Edge AI, Inc. (“Duos Edge AI”), a subsidiary of Duos Technologies Group, Inc. (Nasdaq: DUOT), will host an open house in Dumas, Texas on Tuesday, June 16, 2026, from 9:00 AM to 11:00 AM CDT to showcase the company’s first-of-its-kind Edge Data Center (“EDC”) infrastructure serving Dumas Independent School District (Dumas ISD) and the broader Texas Panhandle region.

Event Details

Date: Tuesday, June 16, 2026
Time: 9:00 AM to 11:00 AM CDT
Location: Dumas Edge Data Center, 421 W. 4th St, Dumas, TX 79029
RSVP:Reserve Your Spot

During the open house, invited guests, partners, community leaders, education stakeholders, and industry representatives will have an opportunity to explore how Duos Edge AI’s localized compute hubs bring advanced data center capabilities to underserved markets, without operational water consumption and with a compact, efficient infrastructure footprint.

The Dumas deployment serves as a regional hub for real-time data processing, enabling advanced educational tools, stronger digital infrastructure, and improved connectivity for 4,300 students across seven campuses. In addition to supporting K-12 education, the facility ensures dependable infrastructure for healthcare, carriers, network providers, enterprises, and the broader regional economy. Guests are encouraged to attend, tour the EDC, and learn more about Duos Edge AI.

“The Panhandle region has been crucial to Duos Edge AI’s journey as we deploy facilities across Texas with a specific focus on rural areas,” said Doug Recker, CEO of Duos Edge AI and Duos Technologies Group, Inc. “Our Dumas facility is already playing a key role in expanding access to advanced computing resources and driving growth throughout the region.”

The open house event will highlight how Duos Edge AI’s modular EDC model can be rapidly deployed, seamlessly integrated with existing network infrastructure, and positioned closer to end users than traditional data center environments. The company’s infrastructure hubs enable robust, water-efficient operations while meeting SOC compliance standards. Designed with scalability in mind, these modular facilities evolve alongside community demands, fostering stronger digital ecosystems and supporting long-term economic development.

By bringing compute power to the edge, Duos Edge AI is helping reduce latency, improve service readiness, and support the growing demand for real-time applications across education, healthcare, business, mobility, and emerging AI use cases.

To register for the open house, visit https://freeevite.com/event.php?e=QNAiq7mZalRfd87nV8tMOw

To learn more about Duos Edge AI, visit www.duosedge.ai.

To learn more about Duos Technologies Group, visit www.duostech.com.

About Duos Technologies Group, Inc.

Duos Technologies Group, Inc. (Nasdaq: DUOT), based in Jacksonville, Florida, through its wholly owned subsidiaries, Duos Technologies, Inc., Duos Edge AI, Inc., and Duos Energy Corporation, designs, develops, deploys and operates intelligent technology solutions for Machine Vision and Artificial Intelligence (“AI”) applications including real-time analysis of fast-moving vehicles, Edge Data Centers, and power consulting. For more information, visit www.duostech.com, www.duosedge.ai and www.duosenergycorp.com.

About Duos Edge AI, Inc.

Duos Edge AI, Inc. is a subsidiary of Duos Technologies Group, Inc. (Nasdaq: DUOT). Duos Edge AI’s mission is to bring advanced technology to underserved communities, particularly in education, healthcare and rural industries, by deploying high-powered edge computing solutions that minimize latency and optimize performance. Duos Edge AI specializes in high-function Edge Data Center (“EDC”) solutions tailored to meet evolving needs in any environment. By focusing on providing scalable IT resources that seamlessly integrate with existing infrastructure, its solutions expand capabilities at the network edge, ensuring data uptime and onsite services. With the ability to provide 100 kW+ per cabinet, rapid 90-day deployment, and continuous 24/7 data services, Duos Edge AI aims to position its edge data centers within 12 miles of end users or devices, significantly closer than traditional data centers. This approach enables timely processing of massive amounts of data for applications requiring real-time response and supporting current and future technologies without large capital investments. For more information, visit www.duosedge.ai.

About Dumas ISD

Dumas Independent School District serves approximately 4,300 students across seven campuses in Dumas and Cactus, Texas. Guided by the motto “Expect Success!”, we are committed to delivering a high-quality education in a safe and supportive learning environment. Our mission is to achieve academic excellence through strong collaboration with students, parents, and the community. We envision a district where every student is prepared to succeed—academically, socially, and personally—while thriving in competitive programs and safe schools. Through ongoing staff development and active community involvement, Dumas ISD fosters growth for the whole child and equips graduates to excel in college, career, and life.

Media Contact

Duos Edge AI
iMiller Public Relations
+1.914.315.6424
[email protected]

EAST RUTHERFORD, NJ, June 04, 2026 (GLOBE NEWSWIRE) —
Mama’s Creations, Inc. (NASDAQ: MAMA), a leading national marketer and manufacturer of fresh Deli prepared foods, today announced that management was invited to participate in three leading investor conferences in Summer 2026: the Oppenheimer 26th Annual Consumer Growth & E-Commerce Conference, the D.A. Davidson 2026 Technology & Consumer Conference, and Planet MicroCap Las Vegas 2026.

Adam L. Michaels, Chairman and CEO of Mama’s Creations, is scheduled to host one-on-one meetings with institutional investors throughout the duration of each event, and host a presentation at Planet MicroCap Las Vegas 2026, as follows:

Oppenheimer 26th Annual Consumer Growth & E-Commerce Conference

Date: June 9, 2026
Location: Virtual
Format: 1×1 Meetings Only

D.A. Davidson 2026 Technology & Consumer Conference

Date: June 11, 2026
Location: Four Seasons, Nashville, TN
Format: 1×1 Meetings Only

Planet MicroCap Las Vegas 2026

Date: June 17-18, 2026
Location: Bellagio, Las Vegas, NV
Format: Presentation & 1×1 Meetings
Presentation: Wednesday, June 17, 2026 at 2:00pm Pacific time
Webcast: https://event.summitcast.com/view/bpjo3VVjZ25pp6SXpUua92/fnBCbbsmJABL6J3qU8rzkL

Adam L. Michaels commented: “This slate of conferences provides a welcome opportunity to engage directly with the institutional investor community on the back of what was a transformational year. Fiscal 2026 saw the addition of Crown 1’s Bay Shore facility, the build-out of a true three-facility manufacturing platform, and meaningful operational progress as our 4Cs framework of Cost, Controls, Culture, and Catapult took firmer hold across the organization.

“We look forward to discussing how we are translating that foundation into accelerating commercial momentum, from expanded tier-1 retail relationships, to a healthy protein-centric product pipeline aligned with the structural shift of consumer preferences into the deli prepared aisle. We are excited to share why we believe Mama’s Creations is uniquely positioned to lead the fresh deli prepared foods category for years to come.”

A live audio webcast and archive of the Planet MicroCap Las Vegas 2026 presentation will be available using the webcast link above. Registration is mandatory for conference participation. For more information or to schedule a meeting with management, please contact MZ Group at [email protected].

About Mama’s Creations, Inc.

Mama’s Creations, Inc. (Nasdaq: MAMA) is a leading marketer and manufacturer of fresh deli prepared foods, found in over 12,000 grocery, mass, club and convenience stores nationally. The Company’s broad product portfolio, born from MamaMancini’s rich history in Italian foods, now consists of a variety of high quality, fresh, clean and easy to prepare foods to address the needs of both our consumers and retailers. Our vision is to become a one-stop-shop deli solutions platform, leveraging vertical integration and a diverse family of brands to offer a wide array of prepared foods to meet the changing demands of the modern consumer. For more information, please visit https://mamascreations.com.

Forward-Looking Statements

This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements include information about management’s view of the Company’s future expectations, plans and prospects, including future business opportunities or strategies and are generally preceded by words such as “anticipate,” “believe,” “eventually,” “expect,” “future,” “may,” “look forward to,” “plan,” “projected,“ “should,” “will,” and other words that convey the uncertainty of future events or outcomes. You are cautioned that such statements are subject to a multitude of known and unknown risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors. Certain of these risk factors and others are included in documents the Company files with the Securities and Exchange Commission, including but not limited to, the Company’s Annual Report on Form 10-K for the year ended January 31, 2024, as well as subsequent reports filed with the Securities and Exchange Commission.

The Company has based these forward-looking statements on its current expectations and assumptions about future events. While management considers these expectations and assumptions to be reasonable, they are inherently subject to significant business, economic, competitive, regulatory, and other factors, contingencies, and uncertainties, most of which are difficult to predict and many of which are beyond the Company’s control. You are urged not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. Except as may be required by applicable law or regulation, the Company’s does not undertake, and specifically disclaims, any obligation to update any forward-looking statements to reflect events or circumstances occurring after the date of such statements.

Investor Relations Contact:

Lucas A. Zimmerman
Managing Director
MZ Group – MZ North America
(949) 259-4987
[email protected]
www.mzgroup.us

– Access the segment

here

HOUSTON, June 04, 2026 (GLOBE NEWSWIRE) — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that Walter Klemp, Chairman and Chief Executive Officer of Moleculin, participated in a Virtual Investor “What This Means” segment.

As part of the segment, Mr. Klemp discussed the Company’s recent news announcing that the 45th subject has been enrolled in its pivotal Phase 2B/3 MIRACLE trial evaluating Annamycin in combination with cytarabine (AnnAraC) for the treatment of adult subjects with relapsed or refractory acute myeloid leukemia (R/R AML). Mr. Klemp gave insight into how this milestone triggers the final phase of preparation for the trial’s interim 45 subject data unblinding, which remains on track for mid-2026 and represents a potentially defining inflection point for the Company.

The segment is now available for on-demand viewing here.

About Moleculin Biotech, Inc.

Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing hard-to-treat tumors and viruses. The Company’s lead program, Annamycin (also known as naxtarubicin), is a next-generation highly efficacious and well tolerated anthracycline designed to avoid multidrug resistance mechanisms and to lack the cardiotoxicity common with currently prescribed anthracyclines. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.

The Company has begun the MIRACLE (Moleculin R/R AML AnnAraC Clinical Evaluation) Trial (MB-108), a pivotal, adaptive design Phase 3 trial evaluating Annamycin in combination with cytarabine, together referred to as AnnAraC (the combination of Annamycin and cytarabine, also referred to as “Ara-C”) for the treatment of relapsed or refractory acute myeloid leukemia. Following a successful Phase 1B/2 study (MB-106), with input from the FDA, the Company believes it has substantially de-risked the development pathway towards a potential approval for Annamycin for the treatment of AML. This study remains subject to appropriate future filings with potential additional feedback from the FDA and their foreign equivalents.

Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers. Moleculin also has in its pipeline a portfolio of antimetabolites, including WP1122 for the potential treatment of pathogenic viruses, as well as certain cancer indications. 

For more information about the Company, please visit www.moleculin.com and connect on X, LinkedIn and Facebook.

Forward-Looking Statements

Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the expected timing and results of the 45-subject interim data unblinding in the MIRACLE trial, the anticipated clinical milestones set forth above, and the potential efficacy and safety of Annamycin and AnnAraC in R/R AML and other indications. Moleculin will require significant additional financing, for which the Company has no commitments, in order to conduct its clinical trials as described in this press release, and the milestones described in this press release assume the Company’s ability to secure such financing on a timely basis. Although Moleculin believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. The Company relies on the reports of its expert with regard to the absence of cardiotoxicity. The dataset referenced in this press release is subject to the review of the data from future subjects in its current and future clinical trials and long-term follow-up with subjects in its current trials. Moleculin has attempted to identify forward-looking statements by terminology including ‘believes,’ ‘estimates,’ ‘anticipates,’ ‘expects,’ ‘plans,’ ‘projects,’ ‘intends,’ ‘potential,’ ‘may,’ ‘could,’ ‘might,’ ‘will,’ ‘should,’ ‘approximately’ or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. “Risk Factors” in our most recently filed Form 10-K filed with the Securities and Exchange Commission (SEC) and updated from time to time in our Form 10-Q filings and in our other public filings with the SEC. Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

Investor Contact:

JTC Team, LLC
Jenene Thomas
(908) 824-0775
[email protected]